Immune Cells Produce Anti-Inflammatory Protein That Could Treat Severe Asthma
Scientists discover how specialized immune cells fight allergic asthma by producing thymosin β4, opening new treatment paths.
Summary
Researchers found that plasmacytoid dendritic cells (pDCs) help control allergic asthma by producing an anti-inflammatory protein called thymosin β4. When these immune cells were removed from mice, asthma symptoms worsened significantly. The study revealed that airway cells release IL-33, which signals pDCs to make thymosin β4. This protein then prevents other immune cells from recruiting inflammatory cells to the lungs. Surprisingly, both mice and humans with active asthma had lower blood levels of thymosin β4, suggesting the protein gets consumed during inflammation.
Detailed Summary
This groundbreaking research reveals a previously unknown protective mechanism in allergic asthma that could lead to new treatments for millions of sufferers worldwide.
Scientists studied plasmacytoid dendritic cells (pDCs), specialized immune cells known for their role in fighting viral infections. Using genetically modified mice, they discovered that pDCs actually help suppress allergic asthma by producing an anti-inflammatory protein called thymosin β4.
When researchers depleted pDCs during asthma attacks, symptoms became dramatically worse. RNA sequencing revealed that thymosin β4 was among the most upregulated genes in lung pDCs during asthma. The cascade begins when damaged airway cells release IL-33, which signals pDCs to ramp up thymosin β4 production. This protein then targets alveolar macrophages, blocking their ability to recruit inflammatory cells that worsen asthma.
Most surprisingly, both asthmatic mice and human patients showed decreased blood levels of thymosin β4 during active disease. This suggests the protein gets rapidly consumed as it works to control inflammation. When researchers supplemented thymosin β4 in mice lacking pDCs, asthma symptoms improved significantly.
These findings challenge the traditional view of pDCs as purely antiviral defenders, revealing their crucial role in controlling allergic inflammation. The discovery could lead to thymosin β4-based therapies for severe asthma, particularly for patients whose current treatments aren't working effectively.
Key Findings
- pDCs produce thymosin β4 protein that suppresses allergic asthma inflammation
- IL-33 from airway cells signals pDCs to increase thymosin β4 production
- Thymosin β4 blocks inflammatory cell recruitment by targeting alveolar macrophages
- Asthmatic patients have lower blood thymosin β4 levels during active disease
- Thymosin β4 supplementation reversed severe asthma symptoms in mice
Methodology
Researchers used BDCA2-DTR transgenic mice for selective pDC depletion, performed RNA sequencing of lung pDCs, and conducted in vitro cell culture experiments. They also used CCR2 blockade and thymosin β4 supplementation to test therapeutic interventions.
Study Limitations
The study was primarily conducted in mouse models with house dust mite allergen. Human validation was limited to serum thymosin β4 measurements, and long-term safety of thymosin β4 supplementation remains unknown.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.